Abstract 15443: Association Between Central Sleep Apnea and P2y12 Inhibitors in Patients with Coronary Heart Disease

Introduction: Central sleep apnea (CSA) is common in patients with heart failure and is associated with a poor prognosis. A number of studies have linked the P2Y12 inhibitor, ticagrelor, with CSA. We aimed to evaluate CSA prevalence in patients with coronary heart disease (CHD) and whether ticagrelor use is associated with CSA in this population. Methods: We reviewed consecutive patients with CHD data who underwent a clinically indicated polysomnography (PSG) test over a 5-year period from three academic sleep centers. We sampled patients who were on ticagrelor or clopidogrel during their PSG test at a 1:4 ticagrelor:clopidogrel ratio. Patients with an active opioid prescription at time of PSG test were excluded. Age, left ventricle (LV) dysfunction (ejection fraction <45%), and P2Y12 inhibitor use were included in a multivariate logistic regression. Results: A total of 141 patients (age 63.7 ± 11.4, 33% female) were included with 30 on ticagrelor and 111 on clopidogrel. 106 (75.2%) patients had undergone percutaneous coronary intervention for ACS. 33 (23.4%) patients had LV dysfunction. The mean apnea hypopnea index (AHI) was 29 (/hr). High CSA burden (central apnea index [CAI] ≥5/h) and strict CSA (AHI ≥5/h and CAI >50% of AHI) were present in 16 (11.3%) and 5 (3.5%) patients, respectively. High CSA burden and strict CSA were more common in patients on ticagrelor than in those on clopidogrel (7 [23.3%] vs. 9 [8.1%] and 3 [10.0%] vs. 2 [1.8%]). In multivariable analysis ticagrelor use was associated with high CSA burden adjusting for LV dysfunction and age (OR 3.27, 95% CI 0.99-10.7, p=0.048). No variables were associated with strict CSA. Conclusions: Ticagrelor use was associated with high CSA burden in patients with coronary heart disease. Future studies should verify these results in a larger cohort and explore their clinical significance.